Combined allergic rhinitis and asthma syndrome (CARAS)

Int Immunopharmacol. 2019 Sep:74:105718. doi: 10.1016/j.intimp.2019.105718. Epub 2019 Jun 27.

Abstract

Combined allergic rhinitis and asthma syndrome (CARAS) is a concept of "one airway - one disease" or "unified airway disease ". The upper and lower airway inflammation characterizes allergic rhinitis and asthma, respectively and both diseases have shown an intimate connection in their genesis, coexistence and similarities as triggered by the same etiological agents; the same inflammatory cell profile and share therapeutic treatment. This review highlights the concept of CARAS by its phenotype, endotype and biomarker classification. Indeed, rhinitis is divided into four major phenotypes: allergic rhinitis; infectious rhinitis; non-infective/non-allergic rhinitis and mixed rhinitis. On the other hand, asthma has no common consensus yet; however, the most accepted classification is based on the stage of life (early- or late- onset asthma) in which the clinical symptoms are presented. Experimental researches where animals develop a syndrome similar to CARAS have been contributed to better understand the pathogenesis of the syndrome. Therefore, the aim of this review is to clarify current terms related to CARAS as definition, phenotypes, endotypes/biomarkers, physiopathology and treatments.

Keywords: Allergic inflammation; Allergic syndrome; Asthma; Disease of the airway; Rhinitis.

Publication types

  • Review

MeSH terms

  • Animals
  • Asthma*
  • Biomarkers
  • Disease Models, Animal
  • Humans
  • Inflammation
  • Phenotype
  • Respiratory System / immunology*
  • Rhinitis, Allergic*
  • Syndrome

Substances

  • Biomarkers